Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Reinhardt

Showing results (191-200 of 223) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study GroupKim Klein, Gertjan Kaspers, Christine J Harrison, et al.
Blood|August 29, 2018
Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study GroupSanne Noort, Martin Zimmermann, Dirk Reinhardt, et al.
Blood|October 17, 2025
Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert PanelC Michel Zwaan, Sarah K Tasian, Richard Aplenc, et al.
British Journal of Haematology|April 21, 2018
An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemiaGertjan J L Kaspers, Denise Niewerth, Bram A J Wilhelm, et al.
Haematologica|July 28, 2011
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaBrian V Balgobind, Iris H I M Hollink, Susan T C J M Arentsen-Peters, et al.
Blood|July 29, 2015
Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international studyHiroto Inaba, Yinmei Zhou, Oussama Abla, et al.
Plos One|January 16, 2013
Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cellsMahban Irandoust, Julian Alvarez Zarate, Isabelle Hubeek, et al.
Blood|February 14, 2014
Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesisJulia Skokowa, Doris Steinemann, Jenny E Katsman-Kuipers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid LeukemiaC Michel Zwaan, Edward A Kolb, Dirk Reinhardt, et al.
Blood|August 27, 2013
Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study groupEva A Coenen, C Michel Zwaan, Dirk Reinhardt, et al.
Pageof 23

Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2015
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study GroupKim Klein, Gertjan Kaspers, Christine J Harrison, et al.
Blood|August 29, 2018
Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study GroupSanne Noort, Martin Zimmermann, Dirk Reinhardt, et al.
Blood|October 17, 2025
Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert PanelC Michel Zwaan, Sarah K Tasian, Richard Aplenc, et al.
British Journal of Haematology|April 21, 2018
An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemiaGertjan J L Kaspers, Denise Niewerth, Bram A J Wilhelm, et al.
Haematologica|July 28, 2011
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaBrian V Balgobind, Iris H I M Hollink, Susan T C J M Arentsen-Peters, et al.
Blood|July 29, 2015
Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international studyHiroto Inaba, Yinmei Zhou, Oussama Abla, et al.
Plos One|January 16, 2013
Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cellsMahban Irandoust, Julian Alvarez Zarate, Isabelle Hubeek, et al.
Blood|February 14, 2014
Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesisJulia Skokowa, Doris Steinemann, Jenny E Katsman-Kuipers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid LeukemiaC Michel Zwaan, Edward A Kolb, Dirk Reinhardt, et al.
Blood|August 27, 2013
Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study groupEva A Coenen, C Michel Zwaan, Dirk Reinhardt, et al.
Pageof 23